Thromb Haemost 1987; 57(01): 041-043
DOI: 10.1055/s-0038-1651058
Original Articles
Schattauer GmbH Stuttgart

HIV Antibody Status and Immunological Abnormalities in Polish Haemophiliacs

S Lopaciuk
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
,
E Kacperska
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
,
Z Gloskowska-Moraczewska
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
,
K Maslanka
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
,
M Uhrynowska
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
,
M Kraj
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
,
H Seyfried
The Laboratory of Blood Coagulation and Haemostasis and the Department of Serology, Institute of Haematology, Warsaw, Poland
› Author Affiliations
Further Information

Publication History

Received 19 June 1986

Accepted after revision 23 October 1986

Publication Date:
06 July 2018 (online)

Preview

Summary

Sera of 520 multitransfused haemophiliacs were examined for antibody to HIV; 447 patients had haemophilia A and 73 had haemophilia B. In 382 patients with haemophilia A and in 62 with haemophilia B solely Polish-made blood products were used for replacement therapy. The remaining haemophiliacs had also received imported clotting factor concentrates prior to the investigation. Only 8 patients (haemophilia A - 7, haemophilia B - 1) developed anti-HIV and all of them had been exposed to commercial concentrates. The analysis of T-cell subsets demonstrated an inverted T4/T8 ratio (less than 1.0) in 7 (30%) of the 23 haemophiliacs treated solely with domestic cryoprecipitate and in 3 (37%) of the 8 seropositive recipients of commercial concentrates. The most frequent alteration in both subgroups was a reduced ratio with either normal absolute numbers or an increase in T8 cells. Increased serum IgG levels were found in 82% of the users of cryoprecipitate and in 75% of the seropositive patients. Serum beta-2-microglobulin level was elevated in 69 and 62% of each subgroup, respectively. The observed immunological abnormalities, at least in the cryoprecipitate treated subgroup, may be causally related to factors other than HIV infection.